Abstract Poster Wall
2023 Kidney Cancer Research Summit
Abstract 33
Phosphorylation of TRAP1 by the tyrosine kinase c-Abl drives prosurvival signaling in renal cell carcinoma
Mark R. Woodford
Abstract 36
Nucleotide excision repair deficiency is a hypoxia regulated, targetable therapeutic vulnerability in clear cell renal cell carcinoma
Zoltan Szallasi
Abstract 41
Creation and implementation of an institutional workflow for systematic collection of fresh renal cell carcinoma tumor biospecimens for investigative studies
Katherine E Sadak
Abstract 43
SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma
Xian-De Liu
Abstract 47
Mapping the Distribution of Brain Metastases in Renal Cell Carcinoma (RCC) and Association with Clinical Features
Ardit Feinaj
Abstract 49
Dissecting metabolic alterations of clear cell renal cell carcinomas one cell at a time
Lucas A. Salas
Abstract 54
PDL1 expression is inherently tied to the epithelial to mesenchymal transition in renal cell carcinoma: implications for immunotherapy
Allison May
Abstract 56
Single Cell Spatial Analysis Identifies Enriched Transcriptomic and Spatial Patterns Among Immunotherapy Resistant Clear Cell Renal Cell Carcinoma Tumors
Alex Soupir
Abstract 60
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study
Mary Jessel
Abstract 66
Characterization of Tumor Response With Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the CLEAR Study (4-Year Median Follow Up)
Robert J. Motzer
Abstract 69
Adjuvant Pembrolizumab for Renal Cell Carcinoma Across UCLA Integrated Staging System Risk Groups and Disease Stage: Subgroup Analyses From the KEYNOTE-564 Study
Toni Choueiri
Abstract 86
Identification of molecular vulnerabilities in aggressive renal cell carcinoma by a small molecule
Ara Jo
Posters: Trials in Progress
Abstract 68
LITESPARK-024: Randomized Phase 1/2 Study of Belzutifan With or Without Palbociclib for Treatment of Advanced Renal Cell Carcinoma
David F. McDermott